argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it intends to increase the number of American Depositary Shares, representing an equal number of ordinary shares, offered in its previously announced initial public offering in the United States to 5 million ADSs.

The completion of the Offering is subject to market and other conditions. The final issuance price per ADS (in USD) sold in the Offering will be determined following the bookbuilding process.

argenx’s ordinary shares are currently listed on the regulated market of Euronext Brussels. argenx has made an application to have its ADSs listed on the NASDAQ Global Stock Market under the symbol “ARGX”. Application will also be made to admit the ordinary shares issued pursuant to the Offering to trading on the regulated market of Euronext Brussels.

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.